January 8, 2010 /
By Geoff Percival
Friday, January 08, 2010
BIOGEN IDEC – the Boston-based pharmaceutical firm which co-owns the Tysabri multiple sclerosis drug with Athlone-based Elan – is set to re-instate monthly updates of outbreaks of PML, the rare brain disease which is a potential side effect of using Tysabri, after announcing four further cases of the condition.
The four new instances of PML were developed by Tysabri users in the US during November and bring the total number of outbreaks amongst users of the treatment to 28. Biogen recently ceased updating on new PML cases on its website, but is likely to release data for December before the end of this month.
++++++++++++++++++++++++++++++++
.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the “Stu’s Views and MS Related News”, weekly M.S. e-newsletter, then please take 20 seconds to register at: https://www.msviewsandnews.org . – Thank you
.
============================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY
